SCHEMBL5543329

SCHEMBL5543329

[CH2]Cc1cccc(Oc2ccccc2C(F)(F)F)c1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FDFT1 P37268 1/20 0.51
MRGPRX4 Q96LA9 1/20 0.43
LTA4H P09960 1/20 0.42
PTGS2 P35354 1/20 0.42
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
SUCNR1 Q9BXA5 1/20 0.40
THRA P10827 1/20 0.40
THRB P10828 1/20 0.40
LPAR1 Q92633 1/20 0.40
LPAR5 Q9H1C0 1/20 0.40
PPARG P37231 2/20 0.40
NR1H2 P55055 3/20 0.39
NR1H3 Q13133 3/20 0.39
AR P10275 6/20 0.39
NR3C1 P04150 1/20 0.38
CNR1 P21554 1/20 0.38
GPR183 P32249 1/20 0.38
CNR2 P34972 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL919975 0.85 FDFT1 (0.51) FDFT1MRGPRX4LTA4HPTGS2MEN1
SCHEMBL8971018 0.77 FDFT1 (0.55) FDFT1SUCNR1LPAR1LPAR5
SCHEMBL8941555 0.76 AR (0.47) FDFT1MRGPRX4LTA4HPTGS2THRA
SCHEMBL6230311 0.76 L3MBTL1 (0.56) FDFT1MEN1KMT2AAR
SCHEMBL5543857 0.76 FAAH (0.51) FDFT1MRGPRX4LTA4HPPARG
SCHEMBL8306595 0.76 ALDH1A1 (0.58) FDFT1LTA4HPTGS2NR1H3AR
SCHEMBL1676646 0.76 LTA4H (0.53) LTA4HPTGS2KMT2ALPAR1LPAR5
SCHEMBL1218850 0.75 KDM4E (0.50) FDFT1LTA4HMEN1KMT2A
SCHEMBL11521654 0.74 LTA4H (0.58) LTA4HPTGS2THRATHRBLPAR1
SCHEMBL5545108 0.74 LPAR1 (0.51) FDFT1MRGPRX4LTA4HPTGS2THRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 FDFT1 852/4885MRGPRX4 3620/4885LTA4H 3452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.